ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lessened its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 134,827 shares of the biotechnology company’s stock after selling 1,433 shares during the period. Principal Financial Group Inc.’s holdings in ADMA Biologics were worth $1,507,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Viewpoint Capital Management LLC increased its position in shares of ADMA Biologics by 18.6% during the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 2,416 shares during the period. Eagle Asset Management Inc. boosted its holdings in shares of ADMA Biologics by 20.2% during the fourth quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 4,367 shares during the period. CWM LLC grew its holdings in shares of ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 4,367 shares in the last quarter. ProShare Advisors LLC increased its position in ADMA Biologics by 9.2% in the 1st quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock worth $358,000 after purchasing an additional 4,570 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new stake in ADMA Biologics in the first quarter worth approximately $31,000. 75.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the transaction, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares in the company, valued at $4,408,712.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock worth $8,224,121 in the last three months. 3.70% of the stock is owned by corporate insiders.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $17.65 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. ADMA Biologics, Inc. has a fifty-two week low of $3.06 and a fifty-two week high of $19.34. The company has a market cap of $4.09 billion, a price-to-earnings ratio of -887.50 and a beta of 0.61. The stock has a fifty day moving average price of $14.81 and a 200-day moving average price of $10.31.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same quarter last year, the company posted ($0.02) EPS. The company’s revenue for the quarter was up 78.4% compared to the same quarter last year. As a group, equities analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on ADMA. Mizuho boosted their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, June 20th. HC Wainwright upped their price objective on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Cantor Fitzgerald upped their target price on shares of ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.